Megan Folkerts

554 total citations
11 papers, 295 citations indexed

About

Megan Folkerts is a scholar working on Infectious Diseases, Molecular Biology and Oncology. According to data from OpenAlex, Megan Folkerts has authored 11 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 4 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Megan Folkerts's work include Gut microbiota and health (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Tuberculosis Research and Epidemiology (3 papers). Megan Folkerts is often cited by papers focused on Gut microbiota and health (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Tuberculosis Research and Epidemiology (3 papers). Megan Folkerts collaborates with scholars based in United States, South Africa and Brazil. Megan Folkerts's co-authors include Lauren Reining, Sarah K. Highlander, John D. Gillece, Jeffrey M. Trent, Nazlı Dizman, Joann Hsu, Sumanta K. Pal, Paulo Gustavo Bergerot, Nicholas Salgia and Manuel Caitano Maia and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Megan Folkerts

8 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Megan Folkerts United States	5	171	165	74	42	41	11	295
Lauren Reining United States	6	173 1.0×	182 1.1×	84 1.1×	37 0.9×	43 1.0×	10	307
Hu Han China	8	297 1.7×	272 1.6×	74 1.0×	47 1.1×	68 1.7×	16	469
Shan Xue China	9	133 0.8×	133 0.8×	82 1.1×	30 0.7×	48 1.2×	28	353
Kiichiro Baba Japan	5	244 1.4×	176 1.1×	35 0.5×	45 1.1×	29 0.7×	6	351
Myriam Benlaïfaoui Canada	3	165 1.0×	169 1.0×	37 0.5×	50 1.2×	20 0.5×	12	241
Aneta Ševčíková Slovakia	9	179 1.0×	90 0.5×	24 0.3×	24 0.6×	30 0.7×	14	272
Keitaro Doi Japan	3	226 1.3×	154 0.9×	32 0.4×	44 1.0×	18 0.4×	6	294
Saba Kurtom United States	4	223 1.3×	209 1.3×	23 0.3×	36 0.9×	92 2.2×	9	328
Zhuxian Zhu China	6	211 1.2×	75 0.5×	48 0.6×	21 0.5×	21 0.5×	13	310

Countries citing papers authored by Megan Folkerts

Since Specialization

Citations

This map shows the geographic impact of Megan Folkerts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan Folkerts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan Folkerts more than expected).

Fields of papers citing papers by Megan Folkerts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan Folkerts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan Folkerts. The network helps show where Megan Folkerts may publish in the future.

Co-authorship network of co-authors of Megan Folkerts

This figure shows the co-authorship network connecting the top 25 collaborators of Megan Folkerts. A scholar is included among the top collaborators of Megan Folkerts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan Folkerts. Megan Folkerts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Ghebrekristos, Yonas, Natalie Beylis, Megan Folkerts, et al.. (2025). Xpert MTB/RIF Ultra-resistant and MTBDR plus- susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing. Antimicrobial Agents and Chemotherapy. 69(3). e0167124–e0167124. 1 indexed citations

Ismail, Nabila, F A Sirgel, Claudia Spies, et al.. (2025). Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing. Antimicrobial Agents and Chemotherapy. 69(8). e0035625–e0035625.

Klopper, Marisa, Yuri F. van der Heijden, Megan Folkerts, et al.. (2024). The Hidden Epidemic of Isoniazid-Resistant Tuberculosis in South Africa. Annals of the American Thoracic Society. 21(10). 1391–1397. 2 indexed citations

Bowers, Jolene R., Hayley D. Yaglom, Crystal M. Hepp, et al.. (2023). Unique Genomic Epidemiology of COVID-19 in the White Mountain Apache Tribe, April to August 2020, Arizona. mSphere. 8(2). e0065922–e0065922. 1 indexed citations

Highlander, Sarah K., Jason M. Wood, John D. Gillece, et al.. (2023). Multi-faceted metagenomic analysis of spacecraft associated surfaces reveal planetary protection relevant microbial composition. PLoS ONE. 18(3). e0282428–e0282428. 4 indexed citations

Wong, Chi Wah, Susan E. Yost, Jin Sun Lee, et al.. (2021). Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot Study. Frontiers in Oncology. 11. 604584–604584. 20 indexed citations

Yaglom, Hayley D., Darrin Lemmer, Megan Folkerts, et al.. (2021). Applying Genomic Epidemiology to Characterize a COVID-19 Outbreak in a Developmentally Disabled Adult Group Home Setting, Arizona. Frontiers in Public Health. 9. 668214–668214. 2 indexed citations

Salgia, Nicholas, Paulo Gustavo Bergerot, Manuel Caitano Maia, et al.. (2020). Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors. European Urology. 78(4). 498–502. 148 indexed citations

Dizman, Nazlı, Joann Hsu, Paulo Gustavo Bergerot, et al.. (2020). Randomized prospective trial assessing Bifidobacterium-containing probiotic supplementation in metastatic renal cell carcinoma (mRCC) patients receiving vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs).. Journal of Clinical Oncology. 38(15_suppl). 5078–5078.

10.

Dizman, Nazlı, Joann Hsu, Paulo Gustavo Bergerot, et al.. (2020). Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma. Cancer Medicine. 10(1). 79–86. 57 indexed citations

11.

Yuan, Yuan, Jin Sun Lee, Susan E. Yost, et al.. (2020). A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. The Oncologist. 26(2). 99–e217. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact